Metrics as of 10/17/2026, 03:50 AM (Berlin time), refresh in progress.
Tvardi Therapeutics Stock
Tvardi Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Imran Alibhai
- Employees
- 12
- Market cap
- $13 M
- IPO
- 31/01/2014
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The…
Tvardi Therapeutics stock: price history
1D
-5.6%
1W
-1.9%
1M
-41.6%
6M
-70.2%
YTD
-76.5%
1Y
-84.4%
2Y
–
5Y
–
10Y
–
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~35% stronger price swings than usual
Ask the agents about Tvardi Therapeutics
Analyst assessment of Tvardi Therapeutics
PRICE TARGET LOW
US$3.00
CONSENSUS
US$8.75
MEDIAN
US$9.50
PRICE TARGET HIGH
US$13.00
0
STRONG BUY
2
BUY
1
HOLD
1
SELL
0
STRONG SELL
4
TOTAL · Buy
As of: 30/07/2026
Tvardi Therapeutics stock metrics
P/E
-0.36
P/B
1.13
EV/EBITDA
0.08
RETURN ON EQUITY
-77.0%
NET MARGIN
0.0%
DEBT/EQUITY
0.02
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
72.2%
FLOAT SHARES
9,628,849
AVG. DAILY VOLUME (30D)
201,597
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Tvardi Therapeutics stock
What does Tvardi Therapeutics do?
Tvardi Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Imran Alibhai, the company employs around 12 people.
The IPO was on 31/01/2014; the stock trades on NASDAQ under the ticker TVRD.
What do analysts say about Tvardi Therapeutics stock?
4 analysts rate the stock, the consensus is Buy (as of 30/07/2026).
The average price target is US$8.75, ranging from US$3.00 to US$13.00, with a median of US$9.50.
This is an external assessment, not a statement by Market Jury.
When does Tvardi Therapeutics report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly 35% stronger than usual.
Does Tvardi Therapeutics pay a dividend?
No, Tvardi Therapeutics currently does not pay a dividend.
Which stocks are comparable to Tvardi Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Tvardi Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Tvardi Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.